CareLit Fachartikel
A novel approach in the treatment of neuroendocrine gastrointestinal tumors: targeting the epidermal growth factor receptor (EGFR) by gefitinib (ZD1839; Iressa)
M Höpfner, A Sutter, B Gerst, M Zeitz, H Scherübl · Zeitschrift für Gastroenterologie · 2004 · Heft 08
Dokument
1162279
CareLit-ID
Jahr
2004
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Therapeutic options to inhibit growth and further spread of metastatic NE tumor disease are still limited. Here, we demonstrate that targeting the EGFR-sensitive tyrosine kinase (TK) by the EGFR-TK inhibitor gefitinib may be a promising future approach for effective growth control of NE tumors. mRNA- and protein expression of EGFR and EGFR-transactivating insulin-like growth factor receptors of three NE tumor cell lines with different growth characteristics was monitored by RT-PCR and flow-cytometry. In either cell line gefitinib induced a time- and dose-dependent growth inhibition by almost 100%. The antiprolif…
Schlagworte
EGFR
Apoptose
Tyrosinkinase
neuroendokrine Tumoren
Tumor
Apoptosis
Caspase 3
After
Zeitschrift für Gastroenterologie
